Products - Luye Pharma Group

Core Products

Rykindo: The first FDA approved new drug in the CNS therapeutic area developed from China

Erzofri: Approved as a new drug for the treatment of schizophrenia and schizoaffective disorder; administered once per month

Ruoxinlin: China’s first class 1 innovative chemical drug independently developed locally for the treatment of major depressive disorder and protected by intellectual property rights

Meibirui: paliperidone palmitate injection

Jinyouping: the world’s first innovative microsphere formulation for treating Parkinson’s disease

Seroquel and Seroquel XR: Atypical anti-psychotic medicines with antidepressant properties

Rivastigmine Transdermal Patch: For the treatment of Alzheimer's disease, including a once-daily patch formulation and a twice-weekly patch formulation

Zepzelca: The only new chemical entity approved by the FDA for the treatment of metastatic SCLC in the past 27 years

Baituowei: The world's only formulation of long-acting goserelin microspheres approved for launch in China

Mimeixin: the only locally made product of oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets in China

Boyounuo: A Biosimilar to Avastin, for the treatment of NSCLC, colorectal cancer, glioblastoma, ovarian cancer,hepatocellular carcinoma and cervical cancer

Boluojia: a biosimilar to Xgeva，approved for marketing in China，undergoing Phase 3 clinical trials in the U.S., Europe and Japan

Lipusu: The only marketed paclitaxel liposome injection in the world indicated for multiple cancers

CMNa: The only chemical sensitizer for cancer radiotherapy in China

Xuezhikang: The first evidence-based and internationally recognized Chinese lipid-regulating drug to have completed Phase II clinical trials in the U.S

Oukai: Obtained a national novel compounds patent and is the only oral Aescinate tablet in China to contain sodium salt, widely to treat soft tissue swelling and venous edema caused by various reasons

Boyoubei: The world's first approved denosumab biosimilar for the treatment of postmenopausal women with osteoporosis at high risk of fractures

Rykindo: The first FDA approved new drug in the CNS therapeutic area developed from China

Erzofri: Approved as a new drug for the treatment of schizophrenia and schizoaffective disorder; administered once per month

Ruoxinlin: China’s first class 1 innovative chemical drug independently developed locally for the treatment of major depressive disorder and protected by intellectual property rights

Meibirui: paliperidone palmitate injection

Jinyouping: the world’s first innovative microsphere formulation for treating Parkinson’s disease

Seroquel and Seroquel XR: Atypical anti-psychotic medicines with antidepressant properties

Rivastigmine Transdermal Patch: For the treatment of Alzheimer's disease, including a once-daily patch formulation and a twice-weekly patch formulation

Zepzelca: The only new chemical entity approved by the FDA for the treatment of metastatic SCLC in the past 27 years

Baituowei: The world's only formulation of long-acting goserelin microspheres approved for launch in China

Mimeixin: the only locally made product of oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets in China

Boyounuo: A Biosimilar to Avastin, for the treatment of NSCLC, colorectal cancer, glioblastoma, ovarian cancer,hepatocellular carcinoma and cervical cancer

Boluojia: a biosimilar to Xgeva，approved for marketing in China，undergoing Phase 3 clinical trials in the U.S., Europe and Japan

Lipusu: The only marketed paclitaxel liposome injection in the world indicated for multiple cancers

CMNa: The only chemical sensitizer for cancer radiotherapy in China

Xuezhikang: The first evidence-based and internationally recognized Chinese lipid-regulating drug to have completed Phase II clinical trials in the U.S

Oukai: Obtained a national novel compounds patent and is the only oral Aescinate tablet in China to contain sodium salt, widely to treat soft tissue swelling and venous edema caused by various reasons

Boyoubei: The world's first approved denosumab biosimilar for the treatment of postmenopausal women with osteoporosis at high risk of fractures

All Products

The following information is for healthcare professionals only.

Oncology Central Nervous System Metabolism Cardiovascular Others

Zepzelca^®（Lurbinectedin for Injection）
The only new chemical entity approved by the U.S. FDA for the treatment of metastatic small cell lung cancer in the past 28 years.

Mimeixin^®（Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets）
The only locally made product of oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets in China.

Baituowei^®（Goserelin Microspheres for Injection）
As the world’s only formulation of long-acting goserelin microspheres approved for launch in China, Baituowei was developed by the company’s world-leading R&D platform for long-acting and extended release drug delivery technology.

Lipusu^® (Paclitaxel Liposome for Injection)
The only marketed paclitaxel liposome injection in the world, used as the first-line chemotherapy for ovarian cancer and subsequent treatment for metastatic carcinoma of ovary. As a first-line chemotherapy, Lipusu® can also be combined with cisplatin.

Boyounuo^® (Bevacizumab Injection)
For the treatment of non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, ovarian cancer and cervical cancer

CMNa^® (Sodium Glycididazole for Injection)
The only chemical sensitizer for cancer radiotherapy in China. Sodium glycididazole, which belongs to the family of nitroimidazole compounds, is a sensitization agent for tumor radiotherapy, and can fix the DNA damage in hypoxic tumor cells caused by radiation and inhibit the repair of DNA damage, and thereby increasing the sensitivity of hypoxic tumor cells to radiation.

Tiandida^® (Amifostine for Injection)
In patients with advanced ovarian cancer or NSCLC who received repeated cisplatin treatments, the drug is used to reduce the cumulative toxicity of cisplatin on the kidneys, without reduction in therapeutic effects of cisplatin. As for head and neck cancer patients undergoing post-operative radiotherapy with exposure window covering the most of the parotid gland, the drug is used for reducing the incidence rate of xerostomia without reducing the therapeutic effect.

Tiandixin^® (Lentinan for Injection)
This product is used as an adjuvant therapy for malignant tumors, malignant (cancerous) hydrothorax and ascites, elderly patients who have repeated respiratory infections, a variety of immunodeficiency patients, chronic hepatitis, herpes zoster and AIDS.

Yitaida^® (Arsenious Acid and Sodium Chloride Injection)
As an antitumor drug, this product is used for acute promyelocytic leukemia and primary advanced liver cancer.

Erzofri^® (paliperidone palmitate)
The first proprietary extended-release injectable of paliperidone palmitate from China to get approved in the U.S.For the treatment of schizophrenia and schizoaffective disorder

Jinyouping^® (Rotigotine Microspheres for Injection)
The world’s first innovative microsphere formulation for treating Parkinson’s disease. For the treatment of Parkinson’s disease

Meibirui^® (Paliperidone Palmitate Injection)
Developed by the company’s R&D platform for long-acting and extended release drug delivery technology.For the treatment of schizophrenia

Rykindo^®(risperidone) for extended-release injectable suspension
Approved for marketing in the U.S. for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

Approved for marketing in China for the treatment of acute and chronic schizophrenia, the significant positive and negative symptoms of various other psychotic states, and for the alleviation of the affective symptoms associated with schizophrenia.

Ruoxinlin^® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets)
China’s first class 1 innovative chemical drug independently developed locally for the treatment of major depressive disorder and protected by intellectual property rights.

Seroquel^® (Quetiapine Fumarate, immediate release, IR)
For the treatment of schizophrenia and manic episodes of bipolar affective disorder.

Seroquel XR^® (Extended release formulation)
For the treatment of schizophrenia and bipolar affective disorder, in some areas approved for the treatment of depression and generalized anxiety disorder.

Rivastigmine Transdermal Patch
For the treatment of Alzheimer's disease, including a once-daily patch formulation and a twice-weekly patch formulation.

Rotigotine Transdermal Patch
For the treatment of the signs and symptoms of early-stage and advanced idiopathic Parkinson's disease (PD) as well as moderate-to-severe idiopathic restless legs syndrome (RLS) in adults.

Boyoubei^® (Denosumab Injection)
For the treatment of postmenopausal women with osteoporosis at high risk of fractures. The drug can significantly reduce the risk of vertebral, non-vertebral and hip fractures within this patient segment.

Beixi^® (Acarbose Capsules)
The only Acarbose capsule in China managing Type 2 diabetes combined with diet control.

Lutingnuo^® (Glutathione for Injection)
This product is indicated as an adjuvant therapy for toxicity caused by alcohol or certain medications (chemotherapy medicines, anti-cancer agents, anti-TB drugs, antidepressants, paracetamol). It is also used as adjuvant therapy for liver damage caused by alcohol, viruses, medicines and other chemicals, and for the treatment of injuries caused by ionizing radiation.

Beitangning^® (Pioglitazone Hydrochloride Capsules)
This product is indicated to control blood glucose in patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM) while combining with diet control and physical exercises.

Nuosen^® (Pantoprazole Sodium for Injection)
This product is used for acute upper digestive tract hemorrhage such as duodenal ulcer, gastric ulcer, acute gastric mucosal lesion, and compound gastric ulcer.

Nuosen^® (Pantoprazole Sodium Enteric Capsules)
The product is indicated for active peptic ulcer (gastric and duodenal ulcer), reflux esophagitis and Zollinger-Ellison syndrome.

Sailimai^® (Montmorillonite Dispersible Tablets)
For acute and chronic diarrhea in adults and children.

Xuezhikang^® (Xuezhikang Capsule)
The first evidence-based and internationally recognized Chinese lipid-adjusting drug which has completed phase II clinical trials required by FDA.

Maitongna^® (Sodium Aescinate for Injection)
An original drug which is possessed of novel compounds patent in China for treatment of cerebral edema, swelling caused by trauma or surgery and venous reflux disorders.

Sidinuo^® (Elcatonin Injection)
For the treatment of osteoporosis and pain caused by osteoporosis.

Glucosamine Hydrochloride Tablets
For the treatment and prevention of osteoarthritis in all parts of the body, including knee joint, hip joint, spine, shoulder, hand and wrist, and ankle joint.

Oulai^® (Compound Sodium Aescinate Gel)
For the treatment of local swelling caused by inflammation, degenerative lesions and trauma.

Oukai^® (Sodium Aescinate Tablets)
For the treatment of soft tissue swelling and venous edema caused by various reasons.

Fengshiye
For nourishing liver and kidney, nourishing blood and dredging collaterals, dispelling wind and removing dampness. For patients who have pain in bones and joints, numbness in limbs, and rheumatic and rheumatoid diseases caused by blood deficiency of liver and kidney, and anemofrigid-damp arthralgia.